Advertisement
UK markets close in 4 hours 51 minutes

  • FTSE 100

    7,830.27
    -46.78 (-0.59%)
     

  • FTSE 250

    19,285.27
    -165.40 (-0.85%)
     

  • AIM

    741.23
    -4.06 (-0.54%)
     

  • GBP/EUR

    1.1675
    -0.0008 (-0.07%)
     

  • GBP/USD

    1.2444
    +0.0005 (+0.04%)
     

  • Bitcoin GBP

    51,918.59
    +2,322.75 (+4.68%)
     

  • CMC Crypto 200

    1,333.34
    +20.71 (+1.60%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CRUDE OIL

    82.29
    -0.44 (-0.53%)
     

  • GOLD FUTURES

    2,396.40
    -1.60 (-0.07%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,712.64
    -124.76 (-0.70%)
     

  • CAC 40

    7,994.40
    -28.86 (-0.36%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Saniona publishes its Annual Report for 2020

Saniona AB
·1-min read

PRESS RELEASE

April 29, 2021

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the English version of the Annual Report for 2020 is now available on the company’s website, www.saniona.com.

For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

This information was submitted for publication, through the agency of the contact persons set out above, at 17.55 CEST on April 29, 2021.

About Saniona
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona’s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical development. Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and is building its corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

Attachment